Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Michael SticherlingU MrowietzMatthias AugustinD ThaçiN MelzerC HentschkeJ KneidlC SiederKristian ReichPublished in: The British journal of dermatology (2017)
Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.